^
    No biomarker
    Oropharyngeal Cancer
    TPF
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    cisplatin + paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    afatinib
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    capecitabine
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    methotrexate
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    carboplatin
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    cetuximab
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    carboplatin + paclitaxel
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    cisplatin + docetaxel
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    nivolumab
    Sensitive: A2 - Guideline
    PD-L1 expression
    Oropharyngeal Cancer
    pembrolizumab
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    cisplatin + paclitaxel + 5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    cisplatin + 5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    5-fluorouracil + hydroxyurea
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    carboplatin + 5-fluorouracil
    Sensitive: A2 - Guideline
    No biomarker
    Oropharyngeal Cancer
    cisplatin
    Sensitive: A2 - Guideline
    ITGAE overexpression
    Oropharyngeal Cancer
    cetuximab
    Sensitive: C3 – Early Trials